| Execution period | Upto 30.09.2030 |
|---|
NSE filing, NSE: ORISSAMINE. Summary written from the filing by ALFA Finder's alert engine.
The Orissa Minerals Development Company Ltd: key numbers
- Share price
- ₹3,222.60
- Market cap
- ₹1,934 Cr
- Revenue (annual)
- ₹94.10 Cr
- Net profit (annual)
- ₹-2.91 Cr
- P/E (TTM)
- 580.5×Sector 16.7×
- Promoter holding
- 50.01%+0.00% QoQ
- FII holding
- 0.59%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from The Orissa Minerals Development Company Ltd
All →The Orissa Minerals Development Company Board Meeting Date
The Orissa Minerals Development Company will hold a board meeting on 03 November 2026 to consider other business. The trading window closes from 27 October to 03 November 2026.
The Orissa Minerals Development Company Management Change
The company has appointed Shri Daya Nidhan Pandey as a Government Nominee Director, effective October 12, 2026, replacing Shri S. Sharad Rao.
The Orissa Minerals Development Company Other Announcement
The company appointed M/s. SDR & Associates as Statutory Auditor for FY 2026-27, based on communication from the Comptroller and Auditor General of India.
The Orissa Minerals Development Company Other Announcement
The ROC Cuttack has granted a two-month extension for the company to hold its 108th Annual General Meeting, now due by 30th November 2026.
The Orissa Minerals Development Company Management Change
RINL nominated Shri GVN Prasad as Non-Executive Director on OMDC's board. The appointment, effective 16 September 2026, replaces Shri Arun Kanti Bagchi.
The Orissa Minerals Development Company Q1 FY27 Results: Turns Profitable, Net Profit ₹3.5 Cr
The Orissa Minerals Development Company Ltd reported revenue from operations of ₹28.6 Cr (+47.4% YoY) and net profit of ₹3.5 Cr for Q1 FY27.
- Key figure
- Net profit ₹3.5 Cr
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.